| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MNKD | Common Stock, $.01 Par Value | Award | $4.79M | +1M | +50.46% | $4.79 | 2.98M | May 22, 2023 | Direct | F1 |
| transaction | MNKD | Common Stock, $.01 Par Value | Tax liability | -$2.4M | -500K | -16.77% | $4.79 | 2.48M | May 22, 2023 | Direct | F2 |
| transaction | MNKD | Common Stock, $.01 Par Value | Sale | -$703K | -150K | -6.04% | $4.69 | 2.33M | May 24, 2023 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 1,500,000 shares. The acquisition of 500,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. |
| F2 | Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. |
| F3 | Transaction occurred pursuant to Rule 10B5-1 Plan. |